WonBiogen Co Ltd

WonBiogen maintains a strong liquidity position with a current ratio of 6.0, indicating a significant buffer of current assets over current liabilities. The company's cash and equivalents amount to KRW 8,259,823,850, which is well above its short-term obligations, and its free cash flow of KRW 5,232,935,080 supports operational flexibility. The low debt-to-equity ratio of 0.02 suggests a conservative capital structure with minimal leverage. In terms of profitability, WonBiogen's return on equity (ROE) of 15.48% and return on assets (ROA) of 13.89% outperform typical industry benchmarks for medical equipment and supplies firms. The company's operating income of KRW 7,764,602,710 and net income of KRW 6,615,248,740 reflect strong margins, supported by a gross profit of KRW 17,815,029,630 on total revenue of KRW 35,244,285,940. WonBiogen's revenue is concentrated in its core medical supply business, with no disclosed geographic diversification in the provided data. The company's operations are entirely based in Korea, and there are no segment disclosures indicating geographic or product diversification. The company's growth trajectory is positive, with a strong free cash flow and operating cash flow of KRW 5,232,935,080 and KRW 8,483,361,350, respectively. While no explicit forward-looking guidance is provided, the capital expenditure of KRW -2,021,513,380 suggests reinvestment in operations rather than expansion. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt load and strong equity position reduce financial risk exposure. Additionally, the absence of dilution risk is supported by equal basic and diluted shares outstanding, indicating no imminent equity issuance. Recent events include the company's transition from a special purpose acquisition company to a medical supply manufacturer, as noted in its description. No recent filings or transcripts are provided in the input data to indicate material changes in operations or strategy.